5 Best Immunotherapy Stocks To Buy Now

3. Immunocore Holdings plc (NASDAQ:IMCR)

Number of Hedge Fund Holders: 17

Immunocore Holdings plc (NASDAQ:IMCR) is a commercial-stage biotechnology company that engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. It is one of the premier immunotherapy stocks to invest in. Immunocore Holdings plc (NASDAQ:IMCR) shares have slid recently after the company announced initial data for its off-the-shelf T cell receptor immunotherapy IMC-F106C from a Phase 1 trial involving patients with solid tumors. A bi-specific protein, based on the Immunocore Holdings plc (NASDAQ:IMCR) therapeutic platform ImmTAC, IMC-F106C, is the company’s first drug candidate to target the PRAME antigen in tumors.

On September 09, investment advisory Jefferies kept an Overweight rating on the Immunocore Holdings plc (NASDAQ:IMCR) stock with a $68 price target. Analyst Michael Yee issued the ratings update. 

Among the hedge funds being tracked by Insider Monkey, Baltimore-based firm Rock Springs Capital Management is a leading shareholder in Immunocore Holdings plc (NASDAQ:IMCR), with 2.7 million shares worth more than $99.7 million.